Short Interest in Exicure, Inc. (NASDAQ:XCUR) Grows By 58.5%

Exicure, Inc. (NASDAQ:XCUR) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 44,700 shares, a growth of 58.5% from the February 28th total of 28,200 shares. Currently, 1.8% of the shares of the stock are short sold. Based on an average trading volume of 76,100 shares, the days-to-cover ratio is currently 0.6 days.

Institutional Investors Weigh In On Exicure

An institutional investor recently bought a new position in Exicure stock. Geode Capital Management LLC purchased a new stake in Exicure, Inc. (NASDAQ:XCUR) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 12,645 shares of the company’s stock, valued at approximately $173,000. Geode Capital Management LLC owned approximately 0.48% of Exicure at the end of the most recent reporting period. 42.82% of the stock is owned by institutional investors.

Exicure Price Performance

XCUR opened at $13.99 on Friday. Exicure has a 1-year low of $1.44 and a 1-year high of $36.00. The stock has a market cap of $36.46 million, a P/E ratio of -6.76 and a beta of 3.84. The stock’s 50 day simple moving average is $11.08 and its 200 day simple moving average is $9.94.

Exicure (NASDAQ:XCUR) last posted its earnings results on Tuesday, March 18th. The company reported ($3.39) earnings per share for the quarter.

About Exicure

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.